Checkpoint inhibitors prod exhausted immune cells into action
Researchers at the Paul-Ehrlich-Institut have succeeded in significantly increasing the killing of Leishmania parasite-infected cells by human immune cells in a new laboratory model using a checkpoint inhibitor. Perspectively, the findings may be useful for the development of immunotherapeutic strategies to combat leishmaniasis.
Issue 4/2017 of the Pharmacovigilance Bulletin is online
Issue 4/2017 of the Pharmacovigilance Bulletin informs about CAR T-cells as a novel therapeutic option in oncology and drug developments in paediatrics ten years after the EU Pediatric Regulation came into force. Other topics include signal evaluation of acute pancreatitis reported in association with an anti-interleukin-6 receptor monoclonal antibody and risk assessment of thromboembolic events in patients with prostate cancer treated with GnRH agonists.
Carola Lübbing-Raukohl – new head of communications at the Paul-Ehrlich-Institut
As per 15 October 2017, Carola Lübbing-Raukohl became the Head of Press and Information Office at the Paul-Ehrlich-Institut (PEI). In her position, she is the speaker of the institute and is responsible for its internal and external communication. Her work, among other things, focuses on the further development of digital channels including social media.